Angelica Lindén Hirschberg 1 , Johannes Bitzer 2 , Antonio Cano 3 , Iuliana Ceausu 4 , Peter Chedraui 5 , et al.
Maturitas. 2021 Apr 14;S0378-5122(21)00061-X.doi: 10.1016/j.maturitas.2021.04.005. Online ahead of print.
Introduction: Vulvovaginal atrophy (VVA) is a chronic condition caused by estrogen deficiency. It affects around 50% of postmenopausal women, reducing their general and sexual quality of life as well as the quality of their personal relationships.
Aim: The aim of this clinical guide is to set out an individualized approach to the management of VVA with topical estrogens and non-hormonal preparations.
Materials and methods: Literature review and consensus of expert opinion.
Summary recommendations: An individualized approach is required for the management of VVA. Topical low-dose estrogens are effective and also alleviate urinary incontinence and prevent recurrent urinary tract infections. Women should not be denied long-term use of topical estrogens as long as they feel that this treatment is of benefit to them, because the safety data are reassuring. Non-hormonal preparations (lubricants and moisturizers) should be the first-line treatment for VVA in women taking adjuvant endocrine therapies for cancers considered to be hormone-dependent. They can be used over the long term.